Phase II
Trial of CD22-targeting antibody drug conjugate being led by The University of Texas MD Anderson Cancer Center
The active pharmaceutical ingredients (API) will be produced according to GMP requirements in a clean room rented from Accessia Pharma, a provider of high-quality pharmaceutical infrastructures
New therapeutic combination is expected to be generally applicable to many solid tumors with high unmet medical need
MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.
Overall response rate at 28 days of 60%, complete response rate of 50%
Immunicum AB announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial.
DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome
The company and the agency discussed the development of SYN-004 (ribaxamase) to prevent antibiotic-mediated Clostridium difficile infection (CDI).
AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days
Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical trial scheduled for 2019, the first milestone will be $30 million.
PRESS RELEASES